UroGen Pharma Reports 10.8% Revenue Growth but Incurred $49.9 Million Net Loss in Q2 2025

UroGen Pharma Ltd. reported its financial results for the second quarter of 2025, revealing a revenue of $24.2 million, an increase of 10.8% from $21.8 million in the same period last year. For the first half of 2025, the company generated $44.5 million in revenue, up from $40.6 million in the first half of 2024. The growth in revenue is attributed to increased sales volume and favorable pricing of its product, Jelmyto, which is used for treating low-grade upper tract urothelial cancer. However, the company also reported a net loss of $49.9 million for the quarter, compared to a loss of $33.4 million in the prior year, reflecting higher operating expenses.

Total operating expenses for the second quarter reached $62.1 million, a significant rise from $45.5 million in the same quarter of 2024. This increase was driven by higher research and development costs, which rose to $18.9 million from $15.4 million, primarily due to increased manufacturing costs for Zusduri, another product recently approved by the FDA. Selling and marketing expenses also surged to $27.9 million, up from $18.9 million, as the company ramped up its commercial activities in preparation for the launch of Zusduri.

UroGen's balance sheet as of June 30, 2025, showed total assets of $208.7 million, a decrease from $285.7 million at the end of 2024. The decline in assets was largely due to a reduction in cash and cash equivalents, which fell to $92.9 million from $172.0 million. The company’s accumulated deficit increased to $900.0 million, up from $806.2 million at the end of 2024, indicating ongoing financial challenges as it continues to invest heavily in product development and commercialization.

Strategically, UroGen achieved a significant milestone with the FDA approval of Zusduri on June 12, 2025, marking it as the first and only FDA-approved treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer. The company estimates the total addressable market for Zusduri to exceed $5 billion, with an annual treatable population of approximately 82,000 patients in the U.S. UroGen has also expanded its workforce to support the commercialization of both Jelmyto and Zusduri, with a customer-facing team of around 100 employees.

Looking ahead, UroGen anticipates continued losses as it focuses on the commercialization of its products and further research and development activities. The company has indicated that it may need to raise additional capital to support its operations, particularly if it cannot generate sufficient cash inflows from product sales. UroGen's management believes that its current cash and marketable securities will fund operations beyond one year, but acknowledges the need for future financing to sustain its growth and development plans.